Functional Imaging Using Diffuse Optical Spectroscopy of Neoadjuvant Chemotherapy Response in Women with Locally Advanced Breast Cancer
暂无分享,去创建一个
M. Yaffe | H. Soliman | J. Zubovits | G. Czarnota | A. Gunasekara | R. Dent | M. Rycroft | J. Spayne
[1] John M Boone,et al. Classification of breast computed tomography data. , 2008, Medical physics.
[2] Kevin Brindle,et al. New approaches for imaging tumour responses to treatment , 2008, Nature Reviews Cancer.
[3] A. Darzi,et al. Diffuse optical imaging of the healthy and diseased breast: A systematic review , 2008, Breast Cancer Research and Treatment.
[4] A. Schneeweiss,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] B. Tromberg,et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy , 2007, Proceedings of the National Academy of Sciences of the United States of America.
[6] M J Yaffe,et al. Whole‐specimen histopathology: a method to produce whole‐mount breast serial sections for 3‐D digital histopathology imaging , 2007, Histopathology.
[7] Michael Gnant,et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF , 2007, Breast Cancer Research and Treatment.
[8] P. Chérel,et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] N. Hylton. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] G. Hortobagyi,et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Berry. Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .
[12] G. Hortobagyi,et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Bruce J Tromberg,et al. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. , 2005, Journal of biomedical optics.
[14] A. Hutcheon,et al. Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast? , 2005, Breast Cancer Research and Treatment.
[15] Soren D. Konecky,et al. Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. , 2005, Medical physics.
[16] Dianne Georgian-Smith,et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.
[17] M. Huang,et al. Utilizing optical tomography with ultrasound localization to image heterogeneous hemoglobin distribution in large breast cancers. , 2005, Neoplasia.
[18] G. Hortobagyi,et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Yong Wang,et al. Time-domain optical mammography Softscan: initial results on detection and characterization of breast tumors , 2004, Photonics North.
[20] S. Lakhani,et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer , 2004, British Journal of Cancer.
[21] J. Ro,et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] B. Tromberg,et al. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study. , 2004, Journal of biomedical optics.
[23] M. Piccart,et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Donald L Weaver,et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A R Padhani,et al. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. , 2001, Clinical radiology.
[26] Britton Chance,et al. Breast imaging technology: Probing physiology and molecular function using optical imaging - applications to breast cancer , 2000, Breast Cancer Research.
[27] L. Svaasand,et al. Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. , 2000, Neoplasia.
[28] R. Carlson,et al. Multidisciplinary Management of Locally Advanced Breast Cancer , 1999, The breast journal.
[29] D. Mankoff,et al. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]‐sestamibi scintimammography , 1999, Cancer.
[30] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] B. Leone,et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1998, The cancer journal from Scientific American.
[32] J E Husband,et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. , 1996, Radiology.
[33] J. Bergh,et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Z. Baloch,et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.
[35] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] G. Hortobagyi,et al. Positron emission tomography with fluorine‐18‐deoxyglucose in the detection and staging of breast cancer , 1993, Cancer.
[37] J L Sunshine,et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.
[38] D. King,et al. Mammography in the assessment of response to medical treatment of large primary breast cancer. , 1993, Clinical radiology.
[39] G. Hortobagyi,et al. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. , 1988, Radiology.
[40] G. Hortobagyi,et al. Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.